Tag Archives: Myriad Genetics

Merrill Lynch Keeps a Sell Rating on Myriad Genetics (MYGN)

Merrill Lynch analyst Derik De Bruin maintained a Sell rating on Myriad Genetics (NASDAQ: MYGN) today and set a price target of $34. The company’s shares opened today at $43.50. According to TipRanks.com, Bruin is a 3-star analyst with an

Morgan Stanley Believes Myriad Genetics (NASDAQ: MYGN) Won’t Stop Here

In a report released today, Steve Beuchaw from Morgan Stanley maintained a Buy rating on Myriad Genetics (NASDAQ: MYGN), with a price target of $49. The company’s shares closed yesterday at $42.84, close to its 52-week high of $44.87. According

A Director at Myriad Genetics is Exercising Options

Yesterday, a Director at Myriad Genetics, Walter Phd Gilbert, exercised options of Myriad Genetics (NASDAQ: MYGN) for $1.19M. Following Walter Phd Gilbert’s last MYGN Sell transaction on December 15, 2017, the stock climbed by 5.6%. In addition to Walter Phd

The E.V.P., General Counsel of Myriad Genetics is Exercising Options

Today, the E.V.P., General Counsel of Myriad Genetics, Richard M. Marsh, exercised options of Myriad Genetics (NASDAQ: MYGN) for $1.26M. In addition to Richard M. Marsh, one other MYGN executive reported Sell trades in the last month. See today’s analyst

Analysts Have Conflicting Sentiments on These Healthcare Companies: Myriad Genetics (NASDAQ: MYGN) and Loxo Oncology (NASDAQ: LOXO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Myriad Genetics (NASDAQ: MYGN) and Loxo Oncology (NASDAQ: LOXO). Myriad Genetics (NASDAQ: MYGN) In a report released today, Steve Beuchaw from Morgan Stanley maintained a

The Exec. VP International Ops of Myriad Genetics is Exercising Options

Today, the Exec. VP International Ops of Myriad Genetics, Gary A. King, exercised options of Myriad Genetics for $1.37M. In addition to Gary A. King, one other MYGN executive reported Sell trades in the last month. The company has a